drugset / Trial / NCT03490344
Short Course Daratumumab in Patients With Multiple Myeloma
Phase 2
Completed
10 enrolled
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination with lenalidomide has on people and their risk of multiple myeloma. The study is also designed to test the amount of remaining myeloma cells in your body after treatment with daratumumab which is known as minimal residual disease (MRD).
Timeline
- Start
- 2018-05-03
- Primary completion
- 2023-03-23
- Completion
- 2023-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | — |